Association of metabolic syndrome with insulin-like growth factors among adults in the US

Saydah, Sharon; Ballard‐Barbash, Rachel; Potischman, Nancy

doi:10.1007/s10552-009-9351-x

Cited by 27 publications

(23 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The IGF1/IGFBP3 ratio was not associated with metabolic syndrome in our study. These findings in older men aged R70 years contrast with previously reported studies in younger and middleaged men (18,(25)(26)(27). In a report of 1463 younger men aged 20-49 years from the Third National Health and Nutrition Examination Survey (NHANES III), men in the lowest quartile of the IGF1/IGFBP3 ratio were three times more likely to meet the same definition of metabolic syndrome (18).…”

Section: Discussioncontrasting

confidence: 64%

“…In a report of 1463 younger men aged 20-49 years from the Third National Health and Nutrition Examination Survey (NHANES III), men in the lowest quartile of the IGF1/IGFBP3 ratio were three times more likely to meet the same definition of metabolic syndrome (18). A separate analysis based on NHANES III data including men aged 50 years and above found that metabolic syndrome was associated with lower levels of IGF1 and a reduced ratio of IGF1/IGFBP3 (25). In a sample of 359 European men aged 30-64 years, IGF1 levels correlated inversely with fasting glucose, and were associated with lipid and obesity/glucose factors in a principal component analysis (26).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

IGF1 and its binding proteins 3 and 1 are differentially associated with metabolic syndrome in older men

Yeap¹,

Chubb²,

Ho³

et al. 2010

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Circulating IGF1 declines with age, and reduced circulating IGF1 is associated with increased cardiovascular mortality in some but not all studies. The relationship between IGF-binding proteins 3 and 1 (IGFBP3 and IGFBP1) with risk of cardiovascular disease remains unclear. We sought to examine associations between IGF1, IGFBP3 and IGFBP1 with metabolic syndrome in older men. Design: Cross-sectional analysis of 3980 community-dwelling men aged R70 years. Methods: Morning plasma levels of IGF1, IGFBP3 and IGFBP1 were assayed. Metabolic syndrome was defined according to National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATPIII) criteria. Results: For IGF1 and IGFBP3, there was a U-shaped relationship, with middle quintiles possessing the lowest odds ratios (OR) for metabolic syndrome (reference Q1, Q3 IGF1: OR 0.74, 95% confidence intervals 0.57-0.96, Q3 IGFBP3: OR 0.67, 0.51-0.87). Increasing IGFBP1 was associated with reduced risk of metabolic syndrome with a dose-response gradient (reference Q1, OR for Q2 to Q5 IGFBP1: 0.56, 0.33, 0.22 and 0.12 respectively, P!0.001). IGF1 was associated with two, IGFBP1 with four and IGFBP3 with all five components of the metabolic syndrome. The ratio of IGF1/IGFBP3 was not associated with metabolic syndrome. Conclusions: In older men, both lower and higher IGF1 and IGFBP3 levels may be metabolically unfavourable. IGFBP1, as a marker of insulin sensitivity, is relevant in the assessment of metabolic syndrome, while the IGF1/IGFBP3 ratio is less informative. Longitudinal follow-up of this cohort would be needed to determine whether these distributions of IGF1, IGFBP3 and IGFBP1 predict incidence of cardiovascular events during male ageing.

show abstract

Section: Discussioncontrasting

confidence: 64%

Section: Discussionmentioning

confidence: 99%

IGF1 and its binding proteins 3 and 1 are differentially associated with metabolic syndrome in older men

Yeap¹,

Chubb²,

Ho³

et al. 2010

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…In cohorts with younger subjects investigating the relationship of IGF1 with the metabolic syndrome, the common finding is an association of low IGF1 concentrations and the metabolic syndrome (12,22,23). In cohorts with older subjects, the findings are more heterogeneous.…”

Section: Discussionmentioning

confidence: 99%

“…In two previous studies on the association of IGF1 with the metabolic syndrome in older populations, U-shaped relationships have been reported (9,10). Others report low IGF1 values to be related to a greater metabolic burden (11,12,13,14). These cohort studies only speculate about the role of this association in the development of CVD over time.…”

Section: Introductionmentioning

confidence: 96%

Serum IGF1, metabolic syndrome, and incident cardiovascular disease in older people: a population-based study

Bunderen

Oosterwerff

Schoor

et al. 2013

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: High as well as low levels of IGF1 have been associated with cardiovascular diseases (CVD). The relationship of IGF1 with (components of) the metabolic syndrome could help to clarify this controversy. The aims of this study were: i) to investigate the association of IGF1 concentration with prevalent (components of) the metabolic syndrome; and ii) to examine the role of (components of) the metabolic syndrome in the relationship between IGF1 and incident CVD during 11 years of follow-up. Methods: Data were used from the Longitudinal Aging Study Amsterdam, a cohort study in a representative sample of the Dutch older population (R65 years). Data were available in 1258 subjects. Metabolic syndrome was determined using the definition of the US National Cholesterol Education Program Adult Treatment Panel III. CVD were ascertained by self-reports and mortality data. Results: Levels of IGF1 in the fourth quintile were associated with prevalent metabolic syndrome compared with the lowest quintile (odds ratio: 1.59, 95% confidence interval (CI) 1.09-2.33). The middle up to the highest quintile of IGF1 was positively associated with high triglycerides in women. Metabolic syndrome was not a mediator in the U-shaped relationship of IGF1 with CVD. Both subjects without the metabolic syndrome and low IGF1 levels (hazard ratio (HR) 1.75, 95% CI 1.12-2.71) and subjects with the metabolic syndrome and high IGF1 levels (HR 2.28, 95% CI 1.21-4.28) demonstrated increased risks of CVD. Conclusions: In older people, high-normal IGF1 levels are associated with prevalent metabolic syndrome and high triglycerides. Furthermore, this study suggests the presence of different pathomechanisms for both low and high IGF1 levels and incident CVD.

show abstract

“…In general patients with a low normal IGF-I who are obese and meet other criteria for metabolic syndrome tend to have a worse cardiovascular disease outcome than those with a mid to high normal IGF-I (50). Clearly many of these subjects have insulin resistance.…”

Section: Igf-i and The Metabolic Syndromementioning

confidence: 99%

Metabolic Actions of Insulin-Like Growth Factor-I in Normal Physiology and Diabetes

Clemmons

2012

Endocrinology and Metabolism Clinics of North America

254

175

View full text Add to dashboard Cite

Synopsis Insulin-like growth factor-I (IGF-I) is closely related to insulin but has distinct metabolic actions. IGF-I is an important stimulant of protein synthesis in muscle but it also stimulates free fatty acid utilization. Important indirect effects of IGF-I that influence metabolism include suppression of growth hormone secretion and at supraphysiologic concentrations suppression of insulin secretion. IGF-I actions are regulated by IGF binding proteins and in obesity and metabolic syndrome there is major dysregulation of IGF binding protein secretion resulting in alterations in the concentration of free IGF-I and IGF-I actions. In type 1 diabetes, IGF-I synthesis is markedly impaired and in type 2 diabetes multiple changes occur in IGF-I actions including sensitization to its mitogenic actions in some target tissues. Administration of IGF-I to patients with extreme insulin resistance results in improvement in glycemic control and IGF-I has been shown to be associated with lowering glucose and enhancing insulin sensitivity in both type 1 and type 2 diabetes. However diabetics are also quite sensitive to stimulation of side effects in response to IGF-I and this has greatly limited its usefulness as a hypoglycemic agent. IGF-I coordinately links growth hormone and insulin actions as well as having direct effects on intermediary metabolism.

show abstract

Association of metabolic syndrome with insulin-like growth factors among adults in the US

Abstract: These findings may prove useful to an understanding of the role of IGF-I in human disease, in particular its relation to metabolic syndrome, diabetes and potentially some cancers.

Cited by 27 publications

References 42 publications

IGF1 and its binding proteins 3 and 1 are differentially associated with metabolic syndrome in older men

IGF1 and its binding proteins 3 and 1 are differentially associated with metabolic syndrome in older men

Serum IGF1, metabolic syndrome, and incident cardiovascular disease in older people: a population-based study

Metabolic Actions of Insulin-Like Growth Factor-I in Normal Physiology and Diabetes

Contact Info

Product

Resources

About